Molecularly Imprinted Polymers (MIPs) as Theranostic Systems for Sunitinib Controlled Release and Self-Monitoring in Cancer Therapy

Parisi, Ortensia Ilaria; Ruffo, Mariarosa; Malivindi, Rocco; Vattimo, Anna Francesca; Pezzi, Vincenzo; Puoci, Francesco

doi:10.3390/pharmaceutics12010041

Cited by 54 publications

(39 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, an effective and prevalent strategy for achieving monitoring is to encapsulate chemotherapeutic drugs into fluorescent nanomaterials of inert carriers or construct nanoparticles with drugs and fluorescent markers. [19][20][21] Nevertheless, the preparation of nanocarriers is not easy and may have potential toxicity. The low drug loading caused by carriers or fluorescent markers severely limits the application of multifunctional therapy.…”

Section: Introductionmentioning

confidence: 99%

Self-Monitoring and Self-Delivery of Self-Assembled Fluorescent Nanoparticles in Cancer Therapy

Li¹,

Yuan²,

Liu³

et al. 2021

IJN

View full text Add to dashboard Cite

Due to the shortcomings of nanocarriers, the development of carrier-free nanodelivery systems has attracted more and more attention in cancer treatment. However, there are few studies on carrier-free nanosystems that can simultaneously achieve monitoring functions. Here a multifunctional carrier-free nanosystem loaded with curcumin and irinotecan hydrochloride was established for the treatment and monitoring of gastric cancer. Methods: In this study, an irinotecan hydrochloride-curcumin nanosystem in the early stage (the system is named SICN) was prepared. Based on the fluorescence of curcumin, flow cytometry, laser confocal microscopy, and zebrafish fluorescence imaging were used to study the monitoring function of SICN in vivo and in vitro. In addition, HGC-27 human gastric cancer cells were used to study SICN cytotoxicity. Results: Flow cytometry and zebrafish fluorescence imaging monitoring results showed that the uptake of SICN was significantly higher than free curcumin, and the excretion rate was lower. SICN had higher accumulation and retention in cells and zebrafish. Laser confocal microscopy monitoring results showed that SICN was internalized into HGC-27 cells through multiple pathways, including macropinocytosis, caveolin, and clathrin-mediated and clathrin -independent endocytosis, and distributed intracellularly throughout the whole cytoplasm, including lysosomes and Golgi apparatus. In vitro cell experiments showed that SICN nanoparticles were more toxic than single components, and HGC-27 cells had more absorption and higher toxicity to nanoparticles under slightly acidic conditions. Conclusion: SICN is a promising carrier-free nanoparticle, and the combination of two single-component therapies can exert a synergistic antitumor effect. When exposed to a tumor acidic environment, SICN showed stronger cytotoxicity due to charge conversion. More importantly, the nanoparticles' self-monitoring function has been developed, opening up new ideas for combined tumor therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Self-Monitoring and Self-Delivery of Self-Assembled Fluorescent Nanoparticles in Cancer Therapy

Li¹,

Yuan²,

Liu³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…MIPs were reported in recent years more for the application in the delivery and controlled release of anticancer agents [ 25 , 35 , 54 , 61 , 65 , 66 , 96 , 141 , 142 , 143 ]. However, most of the studied MIPS supposed for demonstrating their relevancy as DDS use formulations (type and molar ratios of functional monomers, crosslinkers and solvents) ab initio tested for analytical applications [ 144 ] and a few in vivo animal model assessment of the MIP-DDS were performed [ 4 ].…”

Section: Resultsmentioning

confidence: 99%

Developments of Smart Drug-Delivery Systems Based on Magnetic Molecularly Imprinted Polymers for Targeted Cancer Therapy: A Short Review

Sanadgol

Wackerlig

2020

Pharmaceutics

View full text Add to dashboard Cite

Cancer therapy is still a huge challenge, as especially chemotherapy shows several drawbacks like low specificity to tumor cells, rapid elimination of drugs, high toxicity and lack of aqueous solubility. The combination of molecular imprinting technology with magnetic nanoparticles provides a new class of smart hybrids, i.e., magnetic molecularly imprinted polymers (MMIPs) to overcome limitations in current cancer therapy. The application of these complexes is gaining more interest in therapy, due to their favorable properties, namely, the ability to be guided and to generate slight hyperthermia with an appropriate external magnetic field, alongside the high selectivity and loading capacity of imprinted polymers toward a template molecule. In cancer therapy, using the MMIPs as smart-drug-delivery robots can be a promising alternative to conventional direct administered chemotherapy, aiming to enhance drug accumulation/penetration into the tumors while fewer side effects on the other organs. Overview: In this review, we state the necessity of further studies to translate the anticancer drug-delivery systems into clinical applications with high efficiency. This work relates to the latest state of MMIPs as smart-drug-delivery systems aiming to be used in chemotherapy. The application of computational modeling toward selecting the optimum imprinting interaction partners is stated. The preparation methods employed in these works are summarized and their attainment in drug-loading capacity, release behavior and cytotoxicity toward cancer cells in the manner of in vitro and in vivo studies are stated. As an essential issue toward the development of a body-friendly system, the biocompatibility and toxicity of the developed drug-delivery systems are discussed. We conclude with the promising perspectives in this emerging field. Areas covered: Last ten years of publications (till June 2020) in magnetic molecularly imprinted polymeric nanoparticles for application as smart-drug-delivery systems in chemotherapy.

show abstract

“…In this context, our idea is to develop "monoclonal-type" plastic antibodies based on Molecularly Imprinted Polymers (MIPs) for the selective recognition and binding of the RBD of the novel coronavirus SARS-CoV-2 in the aim to block the function of its spike protein (Figure 1.). This kind of polymeric matrices is synthesized by polymerizing functional and crosslinking monomers around the template (Parisi et al, 2014;Parisi et al, 2020a). The selective recognition abilities of the imprinted polymers are due to the formation of a complex between the target analyte and the selected functional monomers during the pre-polymerization step.…”

Section: Patientsmentioning

confidence: 99%

“Monoclonal-type” plastic antibodies for SARS-CoV-2 based on Molecularly Imprinted Polymers

Puoci

Parisi

Dattilo

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

of the ideaOur idea is focused on the development of "monoclonal-type" plastic antibodies based on Molecularly Imprinted Polymers (MIPs) able to selectively bind a portion of the novel coronavirus SARS-CoV-2 spike protein to block its function and, thus, the infection process. Molecular Imprinting, indeed, represents a very promising and attractive technology for the synthesis of MIPs characterized by specific recognition abilities for a target molecule. Given these characteristics, MIPs can be considered tailor-made synthetic antibodies obtained by a templating process.In the present study, the developed imprinted polymeric nanoparticles were characterized in terms of particles size and distribution by Dynamic Light Scattering (DLS) and the imprinting effect and selectivity were investigated by performing binding experiments using the receptor-binding domain (RBD) of the novel coronavirus and the RBD of SARS-CoV spike protein, respectively. Finally, the hemocompatibility of the prepared MIP-based plastic antibodies was also evaluated.

show abstract

Molecularly Imprinted Polymers (MIPs) as Theranostic Systems for Sunitinib Controlled Release and Self-Monitoring in Cancer Therapy

Cited by 54 publications

References 40 publications

Self-Monitoring and Self-Delivery of Self-Assembled Fluorescent Nanoparticles in Cancer Therapy

Self-Monitoring and Self-Delivery of Self-Assembled Fluorescent Nanoparticles in Cancer Therapy

Developments of Smart Drug-Delivery Systems Based on Magnetic Molecularly Imprinted Polymers for Targeted Cancer Therapy: A Short Review

“Monoclonal-type” plastic antibodies for SARS-CoV-2 based on Molecularly Imprinted Polymers

Contact Info

Product

Resources

About